AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Traws Pharma, Inc. Director's Dealing 2019

Sep 11, 2019

35199_dirs_2019-09-11_100ec996-d19f-452f-95f1-125b331fe21e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2019-09-09

Reporting Person: TYNDALL CAPITAL PARTNERS L P (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-09-09	Common Stock	S	400	$2.765	Disposed	796692	Indirect

Footnotes

F1: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.